Vivani Medical, Inc. (VANI)
| Market Cap | 101.03M +29.2% |
| Revenue (ttm) | n/a |
| Net Income | -26.31M |
| EPS | -0.35 |
| Shares Out | 90.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 361,575 |
| Open | 1.150 |
| Previous Close | 1.150 |
| Day's Range | 1.100 - 1.165 |
| 52-Week Range | 0.923 - 1.920 |
| Beta | 3.30 |
| Analysts | Strong Buy |
| Price Target | 3.83 (+241.96%) |
| Est. Earnings | Nov 12, 2026 |
About VANI
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutid... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for VANI stock is "Strong Buy." The 12-month stock price target is $3.83, which is an increase of 241.96% from the latest price.
News
Vivani Medical Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A novel subdermal GLP-1 implant aims to address poor adherence and tolerability in obesity treatment, with promising preclinical and early clinical results. The lead program, NPM-139, is advancing through trials, supported by strong patient and prescriber interest and a partnership with Novo Nordisk.
Vivani Medical Announces Participation in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting ...
Vivani Medical Slides: Investor presentation
Vivani Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data e...
Vivani Medical Quarterly report: Q2 2026
Vivani Medical has published its Q2 2026 quarterly earnings report on August 13, 2026.
Vivani Medical Earnings release: Q2 2026
Vivani Medical released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Vivani Medical announces full enrollment, initial dosing in SLIM-1 trial
Vivani Medical (VANI) announced full enrollment and successful initial dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant being designed to ...
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.
Vivani Medical Transcript: Emerging Growth Conference
A new agreement with Novo Nordisk highlights unique positioning in GLP-1 implant development, with clinical trials for a semaglutide implant set to begin in August. The technology aims to improve adherence, convenience, and long-term outcomes in obesity treatment.
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug imp...
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech comp...
Vivani Medical enters pact with Novo Nordisk to evaluate NPM-139
Vivani Medical (VANI) announced the signing of a new agreement with Novo Nordisk (NVO) to enable Novo Nordisk to evaluate NPM-139, the company’s semaglutide drug implant. NPM-139, which utilizes Vivan...
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug im...
Vivani Medical Slides: Corporate presentation
Vivani Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 6, 2026.
Vivani Medical to merge Cortigent subsidiary with ClearOne
Vivani Medical (VANI) announced that it has entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, ClearOne (CLRO) and a wholly owned subsidiary of…
ClearOne enters into merger agreement with Cortigent
ClearOne (CLRO) entered into a definitive agreement and plan of merger among its wholly-owned subsidiary, Vivani Medical (VANI), and Cortigent, a wholly-owned subsidiary of Vivani, pursuant to which C...
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company's name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) ...
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly-owned ...
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting d...
Vivani receives approval from Bellberry to initiate SLIM-1 trial in Australia
Vivani Medical (VANI) announced that it has received approval from Bellberry, a human research ethics committee, or HREC, in Australia to initiate SLIM-1, a Phase 1 clinical trial of NPM-139,…
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting d...
Vivani Medical initiated with a Buy at Lake Street
Lake Street initiated coverage of Vivani Medical (VANI) with a Buy rating and $4 price target One of the potential unmet needs in the weight management market is a longer-acting…
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
Vivani Medical director buys $2.0M in common stock
In a regulatory filing, Vivani Medical (VANI) disclosed that its director Gregg Williams bought 1.59M shares of common stock on June 15th in a total transaction size of $2.0M. Shares…
Vivani Medical Transcript: Jefferies Global Healthcare Conference 2026
A novel GLP-1 implant aims to address poor adherence and tolerability in obesity treatment by providing steady, long-term drug delivery. Clinical trials for a semaglutide implant are set to begin, with promising preclinical results and strong patient interest supporting commercial potential.